BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Editorial

  RFK Jr. Is Driving a Wedge Into Already Polarized Vaccine Conversations

  When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and Human Services secretary are bringing down the hammer. What happens when there is no middle ground?

  May 1, 2025

   · 

  7 min read

   · 

  Jef Akst
• 

  Earnings

  Moderna Misses Q1 Revenue Expectations, Plans Another $1.5B in Cuts

  Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

  May 1, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Policy

  HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past

  The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and less affordable,” according to vaccine expert Paul Offit. It could also further complicate the picture for companies like Novavax.

  May 1, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Job Trends

  Employee Engagement, Workforce Sentiment Down in 2024

  Global employee engagement fell two percentage points in 2024, according to Gallup, while BioSpace found that workforce sentiment decreased among biopharma professionals. Additionally, a recent BioSpace poll suggests engagement could continue to decline in 2025.

  May 1, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Earnings

  Lilly’s Revenue Leaps 45% Thanks to Zepbound, Mounjaro, Of Course

  To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 billion for the quarter while Zepbound in weight loss booked $2.31 billion.

  May 1, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal

  Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he does not expect major impacts—at least for 2025.

  May 1, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Lilly Unfazed as CVS Picks Novo’s Side in Obesity Market Battle

  Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

  May 1, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Approvals

  J&J Steps Into Crowded Myasthenia Gravis Market With FDA Nod

  With Imaavy, J&J will go toe-to-toe with fellow Big Pharma AstraZeneca, which owns Soliris and Ultomiris.

  May 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  FDA Misses Another Deadline Amid Staff Exodus, Structural Disruptions

  The FDA has lost several senior employees in recent weeks, including some who have been at the agency for more than two decades.

  May 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Multiple sclerosis

  Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint

  According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug development in multiple sclerosis.

  May 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac